The University of Liverpool has been awarded £850,000 from the National Institute for Health Research (NIHR) to further develop an award winning device that could save the lives of women all over the world (University of Liverpool, 2017).

Professor of International Maternal Health, Andrew Weeks, from the Institute of Translational Medicine received the funds from NIHR’s Innovation for Innovation programme (i4i) for the Postpartum Haemorrhage (PPH) Butterfly.

PPH is often defined as the loss of more than 500ml or 1,000ml of blood within the first twenty four hours following childbirth. It is a common maternity emergency affecting 40,000 British women each year. Although it can usually be treated in the UK, many women suffer long lasting complications. Globally it remains a major cause of death and is responsible for around 25% of the 289,000 maternal deaths annually. Although common, its management has changed little over the last thirty years.

Andrew Weeks has developed the PPH Butterfly, a device that not only stops the bleeding immediately, but also helps to diagnose its source. His collaboration with the University of Liverpool’s Department of Medical Physics and Clinical Engineering, Royal Liverpool and Broadgreen Universities Hospital NHS Trust, Liverpool Business Gateway units, Protolabs, Plastribution and Pelican Feminine Health Care, led to the Research Innovation Award in the NIHR NW Research and Innovations awards in 2015. They were also shortlisted for the prestigious Plastics Industry Award in 2015.

The first clinical trials of the device have now been successfully completed. The next phase will see the device tested this summer on women identified as suffering from PPH.

Andrew Weeks, who is also a consultant obstetrician at the Liverpool Women’s Hospital, said “This funding is vital in helping us to take the development of this device forward. It is also a testament to strong partnership working with the University, the NHS and Industry partners. Going forward we are currently developing a training package for those who will be using it with view to the clinical trials this summer.”